

# PT-141 Dosing Chart

A melanocortin receptor agonist approved for hypoactive sexual desire disorder in premenopausal women. Commonly discussed doses: 500 mcg–1.75 mg. The approved product is a fixed-dose autoinjector. Figures here reflect commonly discussed reconstituted vial use.

thelastpeptide.com · Medically reviewed by Charles Maddix, MSN, APRN, PMHNP-BC · Last reviewed 2026-08-02

### FDA STATUS

FDA-approved as Vyleesi (bremelanotide) for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Research-grade PT-141 sold outside that product is not FDA-approved.

### 5 mg vial — units to draw (U-100 syringe)

| Water added | mg/mL | 500 mcg | 1 mg | 1.75 mg |
|-------------|-------|---------|------|---------|
| 1 mL        | 5     | 10 u    | 20 u | 35 u    |
| 2 mL        | 2.5   | 20 u    | 40 u | 70 u    |
| 3 mL        | 1.67  | 30 u    | 60 u | —       |

### 10 mg vial — units to draw (U-100 syringe)

| Water added | mg/mL | 500 mcg | 1 mg | 1.75 mg |
|-------------|-------|---------|------|---------|
| 1 mL        | 10    | 5 u     | 10 u | 17.5 u  |
| 2 mL        | 5     | 10 u    | 20 u | 35 u    |
| 3 mL        | 3.33  | 15 u    | 30 u | 52.5 u  |

"—" means the draw exceeds one syringe at that concentration. Interactive calculator for any combination: [thelastpeptide.com/peptides/pt-141](https://thelastpeptide.com/peptides/pt-141)

PT-141 dose figures are commonly discussed reference information with no approved labeling unless stated above. The Last Peptide is an educational reference and sells nothing. Dosing figures shown here are commonly discussed reference information, not prescriptions or medical advice. Many peptides listed are not FDA-approved. Talk to a licensed clinician before using any peptide.